
USD
( 0.00%
At Close (As of Jan 1, 1970)
$95.55M
Market Cap
-
P/E Ratio
-0.24
EPS
$1.55
52 Week High
$0.49
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$15M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $11K |
| Capital Expenditures | $15M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$15M |
| Cashflow From Financing | $109M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$27M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Context Therapeutics Inc. is a Boston-based late-stage biopharmaceutical company specializing in innovative non-opioid therapies aimed at managing chronic pain. With a robust pipeline that targets critical unmet medical needs, the company is well-positioned to drive advancements in pain management while prioritizing patient safety. By focusing on non-addictive solutions, Context Therapeutics is not only enhancing patient outcomes but also contributing to the broader effort to mitigate opioid dependency, thereby establishing itself as a frontrunner in the evolution of safer pain management alternatives.